Sage Therapeutics to Report Second Quarter 2019 Financial Results on Tuesday, August 6, 2019sa

TARIS Initiates Clinical Trial of TAR-200 in Combination with Opdivo® (nivolumab) for Patients with Muscle-Invasive Bladder Cancer

GBT and Advocates Launch Disease Awareness Campaign Focused on Breaking Down Stigmas Associated with Sickle Cell Disease

REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers

Maze Therapeutics Appoints Drug Development Expert Richard Scheller, Ph.D., to its Board of Directorsm